<p><strong>What it is:</strong> Tirzepatide is a once-weekly injectable that activates <strong>GIP + GLP-1 receptors</strong>, improving metabolic control by reducing appetite, slowing gastric emptying, and improving insulin sensitivity. <a target="_blank" rel="noopener noreferrer nofollow" class="text-[#FF5252] underline text-primary underline-offset-4" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2107519?utm_source=chatgpt.com">New England Journal of Medicine+1</a></p>

<p><strong>Weight loss (people without diabetes):</strong> In the large SURMOUNT-1 trial (72 weeks), tirzepatide produced <strong>substantial, sustained weight loss</strong> versus placebo, with dose-dependent effects (higher doses generally produced more loss). GI side effects (nausea/diarrhea/constipation) were the most common and tended to be dose-related. <a target="_blank" rel="noopener noreferrer nofollow" class="text-[#FF5252] underline text-primary underline-offset-4" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2206038?utm_source=chatgpt.com">New England Journal of Medicine+1</a></p>

<p><strong>Type 2 diabetes control vs semaglutide:</strong> In SURPASS-2 (patients with type 2 diabetes on metformin), tirzepatide (5/10/15 mg) was <strong>noninferior and superior</strong> to semaglutide 1 mg for <strong>HbA1c reduction</strong> and produced <strong>greater weight loss</strong>, with similar GI-type side effects being most common. <a target="_blank" rel="noopener noreferrer nofollow" class="text-[#FF5252] underline text-primary underline-offset-4" href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01324-6/fulltext?utm_source=chatgpt.com">New England Journal of Medicine+1</a></p>

<p><strong>High cardiovascular-risk diabetes population:</strong> In SURPASS-4 (type 2 diabetes with increased CV risk), tirzepatide improved glycemic control and weight compared with insulin glargine, and the study closely tracked CV events and safety signals in a higher-risk population. <a target="_blank" rel="noopener noreferrer nofollow" class="text-[#FF5252] underline text-primary underline-offset-4" href="https://pubmed.ncbi.nlm.nih.gov/34403649/?utm_source=chatgpt.com">PubMed</a></p>

<h3><strong>Top 3 Research Papers (Links)</strong></h3>

<p><strong>SURMOUNT-1 (Obesity, no diabetes) — NEJM (2022)</strong><br>
"Tirzepatide Once Weekly for the Treatment of Obesity." <a target="_blank" rel="noopener noreferrer nofollow" class="text-[#FF5252] underline text-primary underline-offset-4" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2206038?utm_source=chatgpt.com">New England Journal of Medicine+1</a></p>

<p><strong>SURPASS-2 (Type 2 diabetes; vs semaglutide) — NEJM (2021)</strong><br>
"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." <a target="_blank" rel="noopener noreferrer nofollow" class="text-[#FF5252] underline text-primary underline-offset-4" href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01324-6/fulltext?utm_source=chatgpt.com">New England Journal of Medicine+1</a></p>

<p><strong>SURPASS-4 (Type 2 diabetes + increased CV risk; vs insulin glargine) — The Lancet (2021)</strong><br>
"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4)." <a target="_blank" rel="noopener noreferrer nofollow" class="text-[#FF5252] underline text-primary underline-offset-4" href="https://pubmed.ncbi.nlm.nih.gov/34403649/?utm_source=chatgpt.com">PubMed</a></p>
